Hansa Biopharma AB (publ) (OTCMKTS:HNSBF – Get Free Report) shot up 24.6% during mid-day trading on Tuesday . The stock traded as high as $3.65 and last traded at $3.65. 200 shares were traded during trading, a decline of 53% from the average session volume of 425 shares. The stock had previously closed at $2.93.
Hansa Biopharma AB (publ) Stock Performance
The business has a 50 day moving average price of $2.94 and a 200-day moving average price of $2.94.
Hansa Biopharma AB (publ) Company Profile
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.
Featured Articles
- Five stocks we like better than Hansa Biopharma AB (publ)
- Investing In Automotive Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is Forex and How Does it Work?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Read Stock Charts for Beginners
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.